Barclays Slashes Rating on AstraZeneca (AZN) to Underweight
Tweet Send to a Friend
Barclays downgraded AstraZeneca (NYSE: AZN) from Overweight to Underweight.
This article: 45 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 45 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
